Intravenous Ancrod for Treatment of Acute Ischemic Stroke the STAT Study: A Randomized Controlled Trial
Article Abstract:
Ancrod may be beneficial in patients with the symptoms of a stoke. This anticoagulant drug is derived from the venom of the Malaysian pit viper and has been used in Europe and Canada since the 1970s. Researchers randomly assigned 500 patients with symptoms of a stroke to receive intravenous ancrod or placebo for 3 days within 3 hours of symptom onset. Forty-two percent of the patients in the acrod group benefited from the treatment, compared to 34% of the placebo group. There was less disability in the ancrod group but they were more likely to develop bleeding in the brain.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Ancrod--Is Snake Venom an Antidote for Stroke?
Article Abstract:
More research is needed before the drug ancrod can be recommended for the treatment of stroke. Ancrod is an enzyme derived from the venom of the Malaysian pit viper. It reduces blood levels of fibrinogen, which are high in many stroke patients and may be harmful to their health. A study published in 2000 showed that ancrod improved function and led to a 27% increase in the number of patients with complete recovery compared to a placebo. However, it may not be any more effective than tPA. In addition, patients may develop an immune reaction to snake venom.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial
Article Abstract:
The drug ORG 10172 does not appear to improve the long-term outcome of stroke patients. This drug, also called danaparoid sodium, is a form of low-molecular-weight heparin, which is an anticoagulant. Researchers gave 7-day intravenous infusions of ORG 10172 or a placebo to 1,281 stroke patients at 36 medical centers nationwide. Although the drug appeared to benefit those who received it at the end of the 7-day treatment, 30-day outcomes were similar in both groups. More patients who received the drug experienced serious bleeding into the brain compared to those on placebo.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Effect of improving depression care on pain and functional outcomes among older adults with arthritis: a randomized controlled trial
- Abstracts: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial
- Abstracts: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial
- Abstracts: The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: A randomized controlled trial
- Abstracts: A 77-year-old man with rheumatoid arthritis and acute dyspnea and renal failure. A 44-year-old man with pulmonary disease and proctitis